Zacks Investment Research downgraded shares of Wave Life Sciences Pte. Ltd. (NASDAQ:WVE) from a hold rating to a sell rating in a research report released on Tuesday.

According to Zacks, “WAVE Life Sciences Pte. Ltd. is a preclinical biopharmaceutical company. It designs, develops and commercializes nucleic acid therapeutic candidates for Huntington’s disease, Duchenne muscular dystrophy and inflammatory bowel disease. Huntington’s disease, the Company has programs targeting HTT SNP-1 and HTT SNP-2; DMD, targeting Exon 51 and in IBD, it is targeting SMAD7. The Company has late-stage discovery programs in epidermolysis bullosa simplex, in which it is targeting KRT14 SNP-1 and KRT14 SNP-2 and in DMD, it is focused on an additional DMD target, Activin Receptor type IIb. WAVE Life Sciences Pte. Ltd. is based in Singapore. “

WVE has been the topic of several other research reports. JMP Securities restated a buy rating on shares of Wave Life Sciences Pte. in a report on Tuesday, August 16th. Jefferies Group set a $28.00 price objective on shares of Wave Life Sciences Pte. and gave the company a buy rating in a report on Monday, August 15th. Finally, Leerink Swann restated an outperform rating and set a $45.00 price objective on shares of Wave Life Sciences Pte. in a report on Thursday, November 10th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company presently has a consensus rating of Buy and an average target price of $33.60.

Wave Life Sciences Pte. (NASDAQ:WVE) traded down 4.62% during trading on Tuesday, hitting $36.15. 26,429 shares of the company were exchanged. The firm’s 50 day moving average price is $31.96 and its 200-day moving average price is $23.40. Wave Life Sciences Pte. has a 1-year low of $8.95 and a 1-year high of $38.50. The stock’s market capitalization is $848.62 million.

Wave Life Sciences Pte. (NASDAQ:WVE) last released its quarterly earnings results on Monday, August 15th. The company reported ($0.51) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by $0.14. Equities analysts predict that Wave Life Sciences Pte. will post ($2.29) EPS for the current year.

A number of institutional investors have recently modified their holdings of WVE. The Manufacturers Life Insurance Company acquired a new position in shares of Wave Life Sciences Pte. during the third quarter valued at $176,000. Northern Trust Corp raised its stake in Wave Life Sciences Pte. by 174.2% in the third quarter. Northern Trust Corp now owns 91,433 shares of the company’s stock valued at $2,969,000 after buying an additional 58,088 shares in the last quarter. California State Teachers Retirement System raised its stake in Wave Life Sciences Pte. by 1.3% in the third quarter. California State Teachers Retirement System now owns 15,709 shares of the company’s stock valued at $510,000 after buying an additional 200 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its stake in Wave Life Sciences Pte. by 2.4% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 57,306 shares of the company’s stock valued at $1,861,000 after buying an additional 1,346 shares in the last quarter. Finally, Rhumbline Advisers bought a new stake in Wave Life Sciences Pte. during the third quarter valued at approximately $255,000. Institutional investors own 61.15% of the company’s stock.

About Wave Life Sciences Pte.

WAVE Life Sciences Ltd. is a preclinical biopharmaceutical company. The Company focuses on developing its synthetic chemistry platform to develop and commercialize a pipeline of nucleic acid-based therapeutics. It develops nucleic acid therapeutics that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

5 Day Chart for NASDAQ:WVE

Receive News & Stock Ratings for Wave Life Sciences Pte. Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences Pte. Ltd. and related stocks with our FREE daily email newsletter.